Manjie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manjie Zhang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Bin Sun
Research Center for Pharmacoinformatics, College of Pharmacy, Harbin Medical University, Harbin 150081, China
13 shared publications Hao Wang
State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy Harbin Medical University Harbin People's Republic of China
11 shared publicationsHaoyang Du
State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy Harbin Medical University Harbin People's Republic of China
9 shared publicationsWei Gao
State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy Harbin Medical University Harbin People's Republic of China
9 shared publicationsBin Sun
7 shared publicationsJiaxin Liu
State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy Harbin Medical University Harbin People's Republic of China
7 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78230
Targeted Perturbation of Mitochondrial Energy Metabolism via Thermoelectric Nanoflowers for Enhanced Cuproptosis Echoed With Immunotherapy
Cuproptosis, a novel anti‐cancer mechanism, holds significant potential for triggering sequential immunotherapy to enhance anti‐cancer efficacy. However, this cascade effect is often limited by copper efflux mechanisms mediated by the copper‐transporting ATPase (ATP7B), which reduces intracellular copper accumulation and negates cuproptosis. Here, we designed a mitochondria‐targeting thermoelectric nanoplatform to interfere with the electron transport chain (ETC) of mitochondria, causing adenosine triphosphate (ATP) outage to inhibit ATP7B function, thereby enhancing cuproptosis to achieve a synergistic immunotherapy effect. The nanoplatform was fabricated on a thermoelectric copper telluride (Cu 2‐x Te) base, doped with bismuth (Bi) to enhance its performance. The morphology was engineered into nanoflowers (NFs) to greatly expand its surface area, achieving a high photothermal conversion efficiency of 66.88%. The established temperature gradient drives a thermoelectric catalytic process on the material's surface, leading to the generation of substantial superoxide anion radicals (•O 2 − ) to oxidize mitochondrial nicotinamide adenine dinucleotide (NADH), interfering with ETC to impede ATP biosynthesis. We demonstrated that the NFs effectively potentiate cuproptosis and trigger robust immunotherapy, confirming their significant anti‐cancer efficacy both in vitro and in vivo. This study exemplifies a strategy to amplify tumor immunotherapy by enhancing cuproptosis through thermoelectric materials.
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78230
Open AccessTargeted Perturbation of Mitochondrial Energy Metabolism via Thermoelectric Nanoflowers for Enhanced Cuproptosis Echoed With Immunotherapy
Cuproptosis, a novel anti‐cancer mechanism, holds significant potential for triggering sequential immunotherapy to enhance anti‐cancer efficacy. However, this cascade effect is often limited by copper efflux mechanisms mediated by the copper‐transporting ATPase (ATP7B), which reduces intracellular copper accumulation and negates cuproptosis. Here, we designed a mitochondria‐targeting thermoelectric nanoplatform to interfere with the electron transport chain (ETC) of mitochondria, causing adenosine triphosphate (ATP) outage to inhibit ATP7B function, thereby enhancing cuproptosis to achieve a synergistic immunotherapy effect. The nanoplatform was fabricated on a thermoelectric copper telluride (Cu 2‐x Te) base, doped with bismuth (Bi) to enhance its performance. The morphology was engineered into nanoflowers (NFs) to greatly expand its surface area, achieving a high photothermal conversion efficiency of 66.88%. The established temperature gradient drives a thermoelectric catalytic process on the material's surface, leading to the generation of substantial superoxide anion radicals (•O 2 − ) to oxidize mitochondrial nicotinamide adenine dinucleotide (NADH), interfering with ETC to impede ATP biosynthesis. We demonstrated that the NFs effectively potentiate cuproptosis and trigger robust immunotherapy, confirming their significant anti‐cancer efficacy both in vitro and in vivo. This study exemplifies a strategy to amplify tumor immunotherapy by enhancing cuproptosis through thermoelectric materials.
- 12 October 2026
- Published by Elsevier in Biomaterials
- Vol. 338
Nanobowl-confined hydrophobic phase disperses ER-targeted AIE photosensitizers as dynamic aggregates for precision photodynamic therapy
- 12 October 2026
- Published by Elsevier in Biomaterials
- Vol. 338
Nanobowl-confined hydrophobic phase disperses ER-targeted AIE photosensitizers as dynamic aggregates for precision photodynamic therapy
- Open Access
- 10 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (38) , e71708
Pairing GOx With a Potent H 2 O 2 ‐consuming Co‐Cu x O Nanozyme for Starvation/Cuproptosis/Chemodynamic Synergistic Therapy
Combining glucose oxidase (GOx) with peroxidase‐like (POD) nanozymes is a well‐established strategy for synergistic starvation and chemodynamic therapy (CDT). However, the low catalytic efficacy of most nanozymes compared to GOx often leads to wasteful accumulation of hydrogen peroxide (H 2 O 2 ), which can inhibit GOx activity and limit the therapeutic effect. Therefore, enhancing the H 2 O 2 consumption efficiency is critical to unlocking the full potential of this approach. Here, we designed a cobalt‐doped mixed‐valence copper oxide (Co‐Cu x O) nanozyme with metals uniformly dispersed using a polyacrylic acid (PAA) scaffolding method. This nanozyme tightly couples the redox cycles that drive the valence state interconversions of cobalt (Co) and copper (Cu) elements, enabling highly efficient consumption of H 2 O 2 and glutathione (GSH). While Co provides multi‐valent characteristics ideal for Fenton‐like reactions, Cu acts not only as a co‐catalyst but also triggers cuproptosis. We further installed GOx onto the nanozyme surface, allowing H 2 O 2 produced by GOx channels to Co‐Cu x O active sites, thereby further accelerating the catalytic cascade. In vitro experiments demonstrated effective glucose and H 2 O 2 depletion with abundant hydroxyl radical (·OH) generation. When functionalized with hyaluronic acid (HA) for tumor targeting, in vivo experiments demonstrated robust multimodal cell death, confirming the high efficacy of our integrated dual‐enzyme platform.
- 10 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (38) , e71708
Open AccessPairing GOx With a Potent H 2 O 2 ‐consuming Co‐Cu x O Nanozyme for Starvation/Cuproptosis/Chemodynamic Synergistic Therapy
Combining glucose oxidase (GOx) with peroxidase‐like (POD) nanozymes is a well‐established strategy for synergistic starvation and chemodynamic therapy (CDT). However, the low catalytic efficacy of most nanozymes compared to GOx often leads to wasteful accumulation of hydrogen peroxide (H 2 O 2 ), which can inhibit GOx activity and limit the therapeutic effect. Therefore, enhancing the H 2 O 2 consumption efficiency is critical to unlocking the full potential of this approach. Here, we designed a cobalt‐doped mixed‐valence copper oxide (Co‐Cu x O) nanozyme with metals uniformly dispersed using a polyacrylic acid (PAA) scaffolding method. This nanozyme tightly couples the redox cycles that drive the valence state interconversions of cobalt (Co) and copper (Cu) elements, enabling highly efficient consumption of H 2 O 2 and glutathione (GSH). While Co provides multi‐valent characteristics ideal for Fenton‐like reactions, Cu acts not only as a co‐catalyst but also triggers cuproptosis. We further installed GOx onto the nanozyme surface, allowing H 2 O 2 produced by GOx channels to Co‐Cu x O active sites, thereby further accelerating the catalytic cascade. In vitro experiments demonstrated effective glucose and H 2 O 2 depletion with abundant hydroxyl radical (·OH) generation. When functionalized with hyaluronic acid (HA) for tumor targeting, in vivo experiments demonstrated robust multimodal cell death, confirming the high efficacy of our integrated dual‐enzyme platform.
- Open Access
- 11 July 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (30) , e71437
Provoking Potent Cellular Ferroptosis in the Thermo‐Sensitive S‐Phase via CPT‐11 Loaded Janus Nanomedicine for Enhanced Cancer Therapy
Ferroptosis is a promising anticancer strategy, yet its efficacy is limited by insufficient cellular hydrogen peroxide (H 2 O 2 ) levels and intrinsic antioxidant defenses. Meanwhile, mild photothermal therapy (mPTT) enhances ferroptosis by accelerating lipid peroxidation. Herein, we designed a Janus nanoplatform that specifically arrests cells in thermo‐vulnerable S‐phase to maximize the ferroptosis‐sensitizing capacity of mPTT. A Janus architecture with a unique morphology was engineered to incorporate three functional modules: (1) A photothermal half‐bowl composed of polydopamine (PDA) that generates localized hyperthermia under near‐infrared (NIR) laser irradiation; (2) a drug‐loading module utilizing π–π stacking to deliver irinotecan (CPT‐11), which arrests the cell cycle at the heat‐sensitive S‐phase and creates a favorable environment for mPTT; and (3) a ferroptosis‐inducing Fe‐zinc sulfide (ZnS) core anchored to the other half‐bowl, which initiates ferroptosis via Fe 2+ release and amplifies it through the ZnS component. This amplification operates via two mechanisms: hydrogen sulfide (H 2 S)‐mediated catalase (CAT) inhibition elevates H 2 O 2 for the Fenton reaction, while Zn 2+ ‐triggered p53 activation suppresses SLC7A11, disrupting the glutathione (GSH)‐glutathione peroxidase 4 (GPX4) antioxidant axis. The resulting nanoplatform demonstrated excellent antitumor efficacy, with ferroptosis confirmed as critical to its performance. This Janus nanoplatform presents a novel multi‐mechanism cooperative strategy for anticancer therapy centered on ferroptosis.
- 11 July 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (30) , e71437
Open AccessProvoking Potent Cellular Ferroptosis in the Thermo‐Sensitive S‐Phase via CPT‐11 Loaded Janus Nanomedicine for Enhanced Cancer Therapy
Ferroptosis is a promising anticancer strategy, yet its efficacy is limited by insufficient cellular hydrogen peroxide (H 2 O 2 ) levels and intrinsic antioxidant defenses. Meanwhile, mild photothermal therapy (mPTT) enhances ferroptosis by accelerating lipid peroxidation. Herein, we designed a Janus nanoplatform that specifically arrests cells in thermo‐vulnerable S‐phase to maximize the ferroptosis‐sensitizing capacity of mPTT. A Janus architecture with a unique morphology was engineered to incorporate three functional modules: (1) A photothermal half‐bowl composed of polydopamine (PDA) that generates localized hyperthermia under near‐infrared (NIR) laser irradiation; (2) a drug‐loading module utilizing π–π stacking to deliver irinotecan (CPT‐11), which arrests the cell cycle at the heat‐sensitive S‐phase and creates a favorable environment for mPTT; and (3) a ferroptosis‐inducing Fe‐zinc sulfide (ZnS) core anchored to the other half‐bowl, which initiates ferroptosis via Fe 2+ release and amplifies it through the ZnS component. This amplification operates via two mechanisms: hydrogen sulfide (H 2 S)‐mediated catalase (CAT) inhibition elevates H 2 O 2 for the Fenton reaction, while Zn 2+ ‐triggered p53 activation suppresses SLC7A11, disrupting the glutathione (GSH)‐glutathione peroxidase 4 (GPX4) antioxidant axis. The resulting nanoplatform demonstrated excellent antitumor efficacy, with ferroptosis confirmed as critical to its performance. This Janus nanoplatform presents a novel multi‐mechanism cooperative strategy for anticancer therapy centered on ferroptosis.
- Open Access
- 15 June 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
Myristoylation licenses disordered viral VP4 protein to anchor to and perforate the membrane through phase separation
The VP4 protein of enteroviruses, such as Coxsackievirus B3, is a small, intrinsically disordered protein essential for perforating the host cell membrane during viral entry. A key feature of VP4 is its N-terminal myristoylation, which is required for infectivity in some enteroviruses but dispensable in others, suggesting a complex and context-dependent role that is not fully understood. The precise biophysical mechanisms by which this lipid anchor enables a disordered protein to breach a membrane remain unresolved. Here, using Coxsackievirus B3 VP4 as a model system and integrating multi-scale molecular dynamics simulations with confocal microscopy, we demonstrate that myristoylation is not a simple membrane tether but a multi-functional regulator that orchestrates VP4 activity through distinct, hierarchical roles. First, it provides the necessary hydrophobic anchor to recruit the disordered VP4 to the membrane interface. Second, the myristoyl group acts as a key molecular driver that promotes the liquid-liquid phase separation of VP4, leading to the formation of dynamic condensates on the membrane surface. These condensates actively remodel the membrane, generating substantial curvature that, in turn, lowers the free energy barrier for VP4 penetration. Furthermore, we find evidence that the myristoyl group plays a third role in stabilizing the final transmembrane pore. Our findings establish a novel paradigm where a single lipid modification empowers a disordered viral protein to form a functionally potent condensate that mechanically primes and physically breaches the target membrane, a mechanism that may explain the conditional myristoylation requirement across enteroviruses.
- 15 June 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
Open AccessMyristoylation licenses disordered viral VP4 protein to anchor to and perforate the membrane through phase separation
The VP4 protein of enteroviruses, such as Coxsackievirus B3, is a small, intrinsically disordered protein essential for perforating the host cell membrane during viral entry. A key feature of VP4 is its N-terminal myristoylation, which is required for infectivity in some enteroviruses but dispensable in others, suggesting a complex and context-dependent role that is not fully understood. The precise biophysical mechanisms by which this lipid anchor enables a disordered protein to breach a membrane remain unresolved. Here, using Coxsackievirus B3 VP4 as a model system and integrating multi-scale molecular dynamics simulations with confocal microscopy, we demonstrate that myristoylation is not a simple membrane tether but a multi-functional regulator that orchestrates VP4 activity through distinct, hierarchical roles. First, it provides the necessary hydrophobic anchor to recruit the disordered VP4 to the membrane interface. Second, the myristoyl group acts as a key molecular driver that promotes the liquid-liquid phase separation of VP4, leading to the formation of dynamic condensates on the membrane surface. These condensates actively remodel the membrane, generating substantial curvature that, in turn, lowers the free energy barrier for VP4 penetration. Furthermore, we find evidence that the myristoyl group plays a third role in stabilizing the final transmembrane pore. Our findings establish a novel paradigm where a single lipid modification empowers a disordered viral protein to form a functionally potent condensate that mechanically primes and physically breaches the target membrane, a mechanism that may explain the conditional myristoylation requirement across enteroviruses.
- Open Access
- 12 June 2026
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 22 (6) , e1014405
Stage-dependent role of NEK7 in the inactive-to-active conformational transition of NLRP3 monomer
The NLRP3 inflammasome is a multiprotein complex that primes cytokine production in the innate immune system. The inflammasome activation involves the cage-to-disk transition of NLRP3 oligomers, facilitated by the co-factor NEK7 protein. While NEK7’s role in promoting cage disassembly has been reported, its involvement in the large conformational changes of the NLRP3 monomer during activation remains elusive. Here, by using multi-scale simulations, we uncovered a stage-dependent role of NEK7 in the inactive-to-active transition. In the early stage, NEK7 reshapes the dynamics of the highly unstable inactive NLRP3 monomer to resemble active state, priming the conformational transition. In the middle stage, NEK7 impedes progression by populating an intermediate state farther from the active conformation than the NEK7-free counterpart, and structures in this state exhibit reduced allosteric potential toward activation. In the late stage, NEK7 has negligible impact, as the active conformation remains inherently isolated by a high energy barrier regardless of NEK7 presence. This highlights the critical role of oligomeric assembly in enabling monomeric NLRP3 to complete its conformational transition, in agreement with experiment observations. Our work suggests a multilayered activation mechanism where oligomer-level assembly and monomeric conformational changes are coupled, providing new mechanistic insights into this physiologically essential macromolecular process.
- 12 June 2026
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 22 (6) , e1014405
Open AccessStage-dependent role of NEK7 in the inactive-to-active conformational transition of NLRP3 monomer
The NLRP3 inflammasome is a multiprotein complex that primes cytokine production in the innate immune system. The inflammasome activation involves the cage-to-disk transition of NLRP3 oligomers, facilitated by the co-factor NEK7 protein. While NEK7’s role in promoting cage disassembly has been reported, its involvement in the large conformational changes of the NLRP3 monomer during activation remains elusive. Here, by using multi-scale simulations, we uncovered a stage-dependent role of NEK7 in the inactive-to-active transition. In the early stage, NEK7 reshapes the dynamics of the highly unstable inactive NLRP3 monomer to resemble active state, priming the conformational transition. In the middle stage, NEK7 impedes progression by populating an intermediate state farther from the active conformation than the NEK7-free counterpart, and structures in this state exhibit reduced allosteric potential toward activation. In the late stage, NEK7 has negligible impact, as the active conformation remains inherently isolated by a high energy barrier regardless of NEK7 presence. This highlights the critical role of oligomeric assembly in enabling monomeric NLRP3 to complete its conformational transition, in agreement with experiment observations. Our work suggests a multilayered activation mechanism where oligomer-level assembly and monomeric conformational changes are coupled, providing new mechanistic insights into this physiologically essential macromolecular process.
- 10 April 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (8) , 4758-4768
The Disordered JM Motif in RTKs Promotes Classical DFG out Conformation Formation via the Dynamic Effect
Receptor tyrosine kinases (RTKs) are validated anticancer targets, and targeting their DFGout conformations represents a mainstream strategy for developing highly selective type II inhibitors. RTKs can adopt various DFGout conformations, but only the classical conformations with a fully formed back pocket are structurally validated to accommodate type II inhibitors. However, experimentally determined structures of kinases in a classical DFGout conformation are scarce, which presents a significant obstacle for the structure-based design of selective RTK inhibitors. Recently, a conserved disordered motif N-terminal to the kinase domain of RTKs, called the juxtamembrane (JM) motif, has been reported to regulate the binding of inhibitors to the DFGout conformation of VEGFR2, an RTK involved in angiogenesis. In this study, we performed extensive MD simulations to explore the impact of the disordered JM motif on the conformational space of the DFG motif in RTKs and to investigate how that influence may affect inhibitor binding to VEGFR2. We revealed that in VEGFR2, the disordered JM is highly dynamic and forms transient contacts with the kinase domain and consequently fine-tunes the DFGout subconformational space to shift populations from nonclassical to classical DFGout conformations. This dynamic model provides alternative structural explanations underpinning the reported regulatory effects of the JM motif on binding of the inhibitor to VEGFR2. Additionally, we demonstrated that in other RTKs beyond VEGFR2, the disordered JM similarly promotes classical DFGout conformations. Such a role of JM is particularly favorable for creating druggable DFGout conformations that can be exploited for designing high-selectivity type II inhibitors.
- 10 April 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (8) , 4758-4768
The Disordered JM Motif in RTKs Promotes Classical DFG out Conformation Formation via the Dynamic Effect
Receptor tyrosine kinases (RTKs) are validated anticancer targets, and targeting their DFGout conformations represents a mainstream strategy for developing highly selective type II inhibitors. RTKs can adopt various DFGout conformations, but only the classical conformations with a fully formed back pocket are structurally validated to accommodate type II inhibitors. However, experimentally determined structures of kinases in a classical DFGout conformation are scarce, which presents a significant obstacle for the structure-based design of selective RTK inhibitors. Recently, a conserved disordered motif N-terminal to the kinase domain of RTKs, called the juxtamembrane (JM) motif, has been reported to regulate the binding of inhibitors to the DFGout conformation of VEGFR2, an RTK involved in angiogenesis. In this study, we performed extensive MD simulations to explore the impact of the disordered JM motif on the conformational space of the DFG motif in RTKs and to investigate how that influence may affect inhibitor binding to VEGFR2. We revealed that in VEGFR2, the disordered JM is highly dynamic and forms transient contacts with the kinase domain and consequently fine-tunes the DFGout subconformational space to shift populations from nonclassical to classical DFGout conformations. This dynamic model provides alternative structural explanations underpinning the reported regulatory effects of the JM motif on binding of the inhibitor to VEGFR2. Additionally, we demonstrated that in other RTKs beyond VEGFR2, the disordered JM similarly promotes classical DFGout conformations. Such a role of JM is particularly favorable for creating druggable DFGout conformations that can be exploited for designing high-selectivity type II inhibitors.
- Top Cited Papers
- 13 March 2026
- Published by Elsevier in Biomaterials
- Vol. 331, 124140
Near-infrared-driven self-propelled Janus nanomotors penetrate persistent biofilms to deliver anti-inflammatory and photothermal therapies for accelerated wound healing
- 13 March 2026
- Published by Elsevier in Biomaterials
- Vol. 331, 124140
Top Cited PapersNear-infrared-driven self-propelled Janus nanomotors penetrate persistent biofilms to deliver anti-inflammatory and photothermal therapies for accelerated wound healing
- 5 March 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry Letters
- Vol. 17 (11) , 3338-3349
Revealing Dynamics-Mediated Effects of Pathogenic Missense Mutations on Menin Protein Function
Understanding how disease-causing missense mutations (DCMMs) affect protein function is fundamental. As protein dynamics is increasingly recognized as a key regulator of protein function, it is essential to incorporate dynamics into the once heavily emphasized structure-function framework to explain the effects of DCMMs. Although research in this area is emerging, evidence supporting a definitive role of dynamics in mediating the DCMM effects on protein function remains limited. Here, we used Menin─a mutation-prone scaffold protein involved in various pathologies─as a model system to explore the DCMMs' effects on Menin's dynamics and on Menin's interaction with a disordered JunD peptide. By performing MD simulations on 24 clinically confirmed DCMMs coupled with Rosetta conformation energy calculations, we showed that DCMMs do not necessarily destabilize protein stability. Instead, they induce similar dynamic changes in the protein. Using multireplica umbrella sampling to compare binding affinities, we show that DCMMs reduce Menin-JunD affinity by disrupting the conserved dissociation pathway observed in wild-type Menin. The underlying mechanism was revealed through allosteric analysis, which showed that, despite being located far from the JunD binding site, DCMMs uniformly disturbed the coupling between Menin residue E179 and the binding pocket, and forced maintenance of E197-pocket coupling restored the impaired Menin-JunD interactions in DCMMs. Together, these data demonstrate that DCMMs affect Menin-JunD interactions via changing protein dynamics, with allostery playing a crucial role, necessitating the incorporation of dynamics to better explain the effects of DCMMs.
- 5 March 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry Letters
- Vol. 17 (11) , 3338-3349
Revealing Dynamics-Mediated Effects of Pathogenic Missense Mutations on Menin Protein Function
Understanding how disease-causing missense mutations (DCMMs) affect protein function is fundamental. As protein dynamics is increasingly recognized as a key regulator of protein function, it is essential to incorporate dynamics into the once heavily emphasized structure-function framework to explain the effects of DCMMs. Although research in this area is emerging, evidence supporting a definitive role of dynamics in mediating the DCMM effects on protein function remains limited. Here, we used Menin─a mutation-prone scaffold protein involved in various pathologies─as a model system to explore the DCMMs' effects on Menin's dynamics and on Menin's interaction with a disordered JunD peptide. By performing MD simulations on 24 clinically confirmed DCMMs coupled with Rosetta conformation energy calculations, we showed that DCMMs do not necessarily destabilize protein stability. Instead, they induce similar dynamic changes in the protein. Using multireplica umbrella sampling to compare binding affinities, we show that DCMMs reduce Menin-JunD affinity by disrupting the conserved dissociation pathway observed in wild-type Menin. The underlying mechanism was revealed through allosteric analysis, which showed that, despite being located far from the JunD binding site, DCMMs uniformly disturbed the coupling between Menin residue E179 and the binding pocket, and forced maintenance of E197-pocket coupling restored the impaired Menin-JunD interactions in DCMMs. Together, these data demonstrate that DCMMs affect Menin-JunD interactions via changing protein dynamics, with allostery playing a crucial role, necessitating the incorporation of dynamics to better explain the effects of DCMMs.
- 11 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03942
Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti‐Inflammatory and Sonodynamic Therapy of Psoriasis
The interplay between keratinocyte (KC) hyperproliferation and T cell activation underpins psoriasis pathogenesis, posing significant challenges for effective treatment. Here, cell membrane‐coated nanoparticles (CNPs) are designed to simultaneously inhibit T cell activation and KC hyperproliferation for optimized psoriasis therapy. A customized cell membrane is genetically engineered to overexpress the immunoregulatory V‐domain immunoglobulin suppressor of T cell activation (VISTA) protein to enable potent T‐cell inhibition. The encapsulated core is designed as Janus nanoparticles (mSiO 2 &rPMO) for co‐delivery of hydrophilic 5‐aminolevulinic acid (5‐ALA) and hydrophobic tazarotene, facilitating synergistic sonodynamic therapy (SDT) and anti‐inflammatory effects. Mechanistically, under ultrasound stimulation, accumulated protoporphyrin IX (PpIX) derived from 5‐ALA metabolism generates reactive oxygen species (ROS) that inhibit epidermal proliferation, while tazarotene activates retinoic acid receptor gamma (RARγ) to exert anti‐inflammatory effects. Concurrently, the VISTA‐overexpressed membrane enhances anti‐inflammatory responses, further amplifying the anti‐psoriatic effect. CNP efficacy in a psoriatic mouse model is validated, demonstrating mitigated lesion severity, suppressed epidermal hyperplasia, and reduced inflammatory cytokine levels in skin lesions. Notably, CNPs outperformed non‐membrane counterparts in both cellular and animal models, highlighting the anti‐psoriatic amplification conferred by the engineered membrane. Overall, this research presents a novel therapeutic strategy for psoriasis management using engineered membrane‐coated mesoporous Janus nanoparticles to target keratinocyte proliferation and T cell activation.
- 11 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03942
Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti‐Inflammatory and Sonodynamic Therapy of Psoriasis
The interplay between keratinocyte (KC) hyperproliferation and T cell activation underpins psoriasis pathogenesis, posing significant challenges for effective treatment. Here, cell membrane‐coated nanoparticles (CNPs) are designed to simultaneously inhibit T cell activation and KC hyperproliferation for optimized psoriasis therapy. A customized cell membrane is genetically engineered to overexpress the immunoregulatory V‐domain immunoglobulin suppressor of T cell activation (VISTA) protein to enable potent T‐cell inhibition. The encapsulated core is designed as Janus nanoparticles (mSiO 2 &rPMO) for co‐delivery of hydrophilic 5‐aminolevulinic acid (5‐ALA) and hydrophobic tazarotene, facilitating synergistic sonodynamic therapy (SDT) and anti‐inflammatory effects. Mechanistically, under ultrasound stimulation, accumulated protoporphyrin IX (PpIX) derived from 5‐ALA metabolism generates reactive oxygen species (ROS) that inhibit epidermal proliferation, while tazarotene activates retinoic acid receptor gamma (RARγ) to exert anti‐inflammatory effects. Concurrently, the VISTA‐overexpressed membrane enhances anti‐inflammatory responses, further amplifying the anti‐psoriatic effect. CNP efficacy in a psoriatic mouse model is validated, demonstrating mitigated lesion severity, suppressed epidermal hyperplasia, and reduced inflammatory cytokine levels in skin lesions. Notably, CNPs outperformed non‐membrane counterparts in both cellular and animal models, highlighting the anti‐psoriatic amplification conferred by the engineered membrane. Overall, this research presents a novel therapeutic strategy for psoriasis management using engineered membrane‐coated mesoporous Janus nanoparticles to target keratinocyte proliferation and T cell activation.